Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy

Botulinum toxin type A (BoNT-A) is used in cerebral palsy (CP) for more than 20 years. Nevertheless, the unified protocol of injections and doses does not exist by now. The correct selection of target muscles for BoNT-A injections is based on the experience of the doctor, detailed analysis of neurol...

Full description

Saved in:
Bibliographic Details
Main Authors: A. L. Kurenkov, O. A. Klochkova, B. I. Bursagova, L. M. Kuzenkova, Kh. M. Karimova, A. M. Mamedyarov, A. R. Artemenko, S. A. Petrova
Format: Article
Language:Russian
Published: ABV-press 2015-02-01
Series:Нервно-мышечные болезни
Subjects:
Online Access:https://nmb.abvpress.ru/jour/article/view/27
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849240919658725376
author A. L. Kurenkov
O. A. Klochkova
B. I. Bursagova
L. M. Kuzenkova
Kh. M. Karimova
A. M. Mamedyarov
A. R. Artemenko
S. A. Petrova
author_facet A. L. Kurenkov
O. A. Klochkova
B. I. Bursagova
L. M. Kuzenkova
Kh. M. Karimova
A. M. Mamedyarov
A. R. Artemenko
S. A. Petrova
author_sort A. L. Kurenkov
collection DOAJ
description Botulinum toxin type A (BoNT-A) is used in cerebral palsy (CP) for more than 20 years. Nevertheless, the unified protocol of injections and doses does not exist by now. The correct selection of target muscles for BoNT-A injections is based on the experience of the doctor, detailed analysis of neurological and orthopedic status of the patient, standard scales to evaluate motor potential of the patient. The article represents the detailed review of international clinical trials for multi-level use of BoNT-A in CP and recommendations on doses calculation. Based on our own observations of efficacy and safety of single-used doses of Botox we present the recommended dose ranges for upper and lower limb that led to clinically significant decrease of spasticity with no undesirable weakness. The review of clinical cases presents the doses per targeted muscle and total doses we used, they are advisory in nature.
format Article
id doaj-art-e645140aa7544a6b948e33aef57b3b26
institution Kabale University
issn 2222-8721
2413-0443
language Russian
publishDate 2015-02-01
publisher ABV-press
record_format Article
series Нервно-мышечные болезни
spelling doaj-art-e645140aa7544a6b948e33aef57b3b262025-08-20T04:00:20ZrusABV-pressНервно-мышечные болезни2222-87212413-04432015-02-0103284110.17650/2222-8721-2014-0-3-28-4121Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsyA. L. Kurenkov0O. A. Klochkova1B. I. Bursagova2L. M. Kuzenkova3Kh. M. Karimova4A. M. Mamedyarov5A. R. Artemenko6S. A. Petrova7Research Center of Child Health, MoscowResearch Center of Child Health, MoscowResearch Center of Child Health, MoscowResearch Center of Child Health, MoscowResearch Center of Child Health, MoscowResearch Center of Child Health, MoscowI.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian FederationResearch Center of Child Health, MoscowBotulinum toxin type A (BoNT-A) is used in cerebral palsy (CP) for more than 20 years. Nevertheless, the unified protocol of injections and doses does not exist by now. The correct selection of target muscles for BoNT-A injections is based on the experience of the doctor, detailed analysis of neurological and orthopedic status of the patient, standard scales to evaluate motor potential of the patient. The article represents the detailed review of international clinical trials for multi-level use of BoNT-A in CP and recommendations on doses calculation. Based on our own observations of efficacy and safety of single-used doses of Botox we present the recommended dose ranges for upper and lower limb that led to clinically significant decrease of spasticity with no undesirable weakness. The review of clinical cases presents the doses per targeted muscle and total doses we used, they are advisory in nature.https://nmb.abvpress.ru/jour/article/view/27botulinum toxin type acerebral palsyspasticityspastic diplegiahemiparesisspastic tetraparesisneuroorthopedicsantispasticity medicationsgoals of treatmentashworth scaletardieu scalegross motor function classification system
spellingShingle A. L. Kurenkov
O. A. Klochkova
B. I. Bursagova
L. M. Kuzenkova
Kh. M. Karimova
A. M. Mamedyarov
A. R. Artemenko
S. A. Petrova
Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy
Нервно-мышечные болезни
botulinum toxin type a
cerebral palsy
spasticity
spastic diplegia
hemiparesis
spastic tetraparesis
neuroorthopedics
antispasticity medications
goals of treatment
ashworth scale
tardieu scale
gross motor function classification system
title Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy
title_full Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy
title_fullStr Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy
title_full_unstemmed Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy
title_short Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy
title_sort use of botulinum toxin type a botox in the treatment of infantile cerebral palsy
topic botulinum toxin type a
cerebral palsy
spasticity
spastic diplegia
hemiparesis
spastic tetraparesis
neuroorthopedics
antispasticity medications
goals of treatment
ashworth scale
tardieu scale
gross motor function classification system
url https://nmb.abvpress.ru/jour/article/view/27
work_keys_str_mv AT alkurenkov useofbotulinumtoxintypeabotoxinthetreatmentofinfantilecerebralpalsy
AT oaklochkova useofbotulinumtoxintypeabotoxinthetreatmentofinfantilecerebralpalsy
AT bibursagova useofbotulinumtoxintypeabotoxinthetreatmentofinfantilecerebralpalsy
AT lmkuzenkova useofbotulinumtoxintypeabotoxinthetreatmentofinfantilecerebralpalsy
AT khmkarimova useofbotulinumtoxintypeabotoxinthetreatmentofinfantilecerebralpalsy
AT ammamedyarov useofbotulinumtoxintypeabotoxinthetreatmentofinfantilecerebralpalsy
AT arartemenko useofbotulinumtoxintypeabotoxinthetreatmentofinfantilecerebralpalsy
AT sapetrova useofbotulinumtoxintypeabotoxinthetreatmentofinfantilecerebralpalsy